Cochrane Review Group
Eyes and Vision
171 systematic reviews in Eyes and Vision ask 2,112 questions. 27.8% have no studies to answer them, 21.1% rest on very low certainty evidence and 20.2% reach moderate or high certainty.
Reviews
171
Questions
2,112
current versions
No studies
27.8%
Moderate or high
20.2%
No studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
LipiFlow vs basic warm compresses Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
LipiFlow vs thermostatic devices Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 4 studies · 445 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibomian gland expression scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | SMD 1.31 | 2 studies · 76 participants | Very low |
LipiFlow vs basic warm compresses Mean change from baseline in meibum quality scores at 1 to 4 weeks (higher is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | 1 study · 46 participants | Very low |
LipiFlow vs thermostatic devices Mean change from baseline in symptom scores at 1 to 4 weeks (lower is favored) · people with dry eye LipiFlow for the treatment of dry eye disease (2024) · Cochrane | no estimate extracted | NR | Very low |
Face‐down positioning vs other positioning Proportion of eyes with retinal displacement at 6 months or later (RR < 1 favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | RR 0.73 [0.54, 0.99] | 1 study · 239 participants | Very low |
Face‐down positioning vs other positioning Mean change in logMAR or Snellen visual acuity from baseline to 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Face‐down positioning vs other positioning Mean objective distortion score at 3 months or later (lower is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | MD 1.8 | 1 study · 219 participants | Very low |
Face‐down positioning vs other positioning Quality of life assessments at 3 months or later (higher is favored) · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 217 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | 1 study · 262 participants | Very low |
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | NR | No studies |
Lutein with or without zeaxanthin vs placebo Adverse effects · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | OR 1.06 | NR | Very low |
Reviews 171
Vitrectomy for idiopathic macular hole
CochraneSoF table
7 questions
Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration
CochraneSoF table
6 questions
Corneal collagen cross‐linking for treating keratoconus
CochraneSoF table
7 questions
5‐Fluorouracil for glaucoma surgery
CochraneSoF table
36 questions
Anti‐vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion
CochraneSoF table
7 questions
Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age‐related cataract
CochraneSoF table
6 questions
Phacoemulsification with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age‐related cataract
CochraneSoF table
6 questions
Accommodative intraocular lens versus standard monofocal intraocular lens implantation in cataract surgery
CochraneSoF table
7 questions
Deep anterior lamellar keratoplasty versus penetrating keratoplasty for treating keratoconus
CochraneSoF table
13 questions
Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration
CochraneSoF table
7 questions
Laser photocoagulation for proliferative diabetic retinopathy
CochraneSoF table
7 questions
Laser‐assisted in‐situ keratomileusis (LASIK) versus photorefractive keratectomy (PRK) for myopia
CochraneSoF table
6 questions
Interventions for improving adherence to ocular hypotensive therapy
CochraneSoF table
13 questions
Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus phacoemulsification with posterior chamber intraocular lens for age‐related cataract
CochraneSoF table
6 questions
Ivermectin for onchocercal eye disease (river blindness)
CochraneSoF table
14 questions
Beta radiation for glaucoma surgery
CochraneSoF table
3 questions
Sublingual immunotherapy for treating allergic conjunctivitis
CochraneSoF table
7 questions
Orientation and mobility training for adults with low vision
CochraneSoF table
1 questions
Submacular surgery for choroidal neovascularisation secondary to age‐related macular degeneration
CochraneSoF table
7 questions
Photodynamic therapy for neovascular age‐related macular degeneration
CochraneSoF table
5 questions
Intraoperative Mitomycin C for glaucoma surgery
CochraneSoF table
6 questions